Search Results 8631-8640 of 36783 for oral
Treatment was 160 mg of oral zanubrutinib twice daily (n = 50) or 320 mg once daily (n = 23). Efficacy endpoints included overall response rate (ORR) and ...
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib; Women of ...
Cladribine, mitoxantrone, or oral cyclophosphamide at any time. Treatment with any investigational agent within 24 weeks or 5 drug-elimination half-lives of ...
Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use ...
Able to swallow oral medication. Both female and male patients of reproductive potential must agree to avoid pregnancy or impregnating a partner ...
Sinonasal Outcomes Using Oral Corticosteroids in Patients with Chronic Rhinosinusitis with Nasal Polyps and Positive Sinonasal Cultures. Int Arch ...
For participants with a history of AF or atrial flutter, not on adequate anticoagulant therapy via non-vitamin K oral anticoagulants or warfarin if the ...
iation therapy, Oral and throat cancer, Prostate cancer, Bladder cancer, Head and neck cancer, Skin cancer, Oropharyngeal cancer, Thyroid cancer, Laryngeal ...
ructive surgery, Oral surgery, Skin cancer excision, Microvascular reconstruction, Transoral laser microsurgery, Facial reconstruction, Parotid gland ...
... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!